Payment overview · 2025
General Payments
$790.48
14 reported records · 10 companies
Healthcare provider profile · identity verified
Asim Guha Roy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1083659528
Verified facts
What the public records show
CMS Open Payments records show Asim Guha Roy, MD received $790.48 in general payments during 2025 across 14 reported records.
UCB, Inc. accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Nexletol.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexletol by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $299.80 | 37.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.09 | 15.4% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $121.46 | 15.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $69.99 | 8.8% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $53.36 | 6.8% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $34.22 | 4.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $26.28 | 3.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.43 | 3.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.28 | 2.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.57 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $790.48 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $250.00 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $122.09 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $121.46 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $69.99 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $53.36 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $49.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.28 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.28 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 941 | 153 |
| Gabapentin | Gabapentin | 826 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 604 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 603 | 92 |
| Lisinopril | Lisinopril | 551 | 74 |
| Famotidine | Famotidine | 393 | 54 |
| Donepezil Hcl | Donepezil Hcl | 378 | 44 |
| Furosemide | Furosemide | 377 | 64 |
| Metformin Hcl | Metformin Hcl | 350 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 348 | 50 |
| Eliquis | Apixaban | 343 | 43 |
| Trazodone Hcl | Trazodone Hcl | 318 | 47 |
| Mirtazapine | Mirtazapine | 310 | 47 |
| Sertraline Hcl | Sertraline Hcl | 284 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 280 | 50 |
| Losartan Potassium | Losartan Potassium | 277 | 46 |
| Memantine Hcl | Memantine Hcl | 275 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 259 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 246 | 35 |
| Simvastatin | Simvastatin | 221 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 29 |
| Carvedilol | Carvedilol | 215 | 35 |
| Olanzapine | Olanzapine | 210 | 27 |
| Divalproex Sodium | Divalproex Sodium | 189 | 29 |
| Omeprazole | Omeprazole | 188 | 34 |
| Potassium Chloride | Potassium Chloride | 185 | 33 |
| Levetiracetam | Levetiracetam | 168 | 24 |
| Januvia | Sitagliptin Phosphate | 150 | 13 |
| Alendronate Sodium | Alendronate Sodium | 146 | 29 |
| Risperidone | Risperidone | 144 | 19 |
| Aripiprazole | Aripiprazole | 135 | 17 |
| Buspirone Hcl | Buspirone Hcl | 127 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 28 |
| Baclofen | Baclofen | 123 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 104 | 20 |
| Latanoprost | Latanoprost | 101 | 16 |
| Finasteride | Finasteride | 100 | 15 |
| Tramadol Hcl | Tramadol Hcl | 100 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 17 |
| Lactulose | Lactulose | 94 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 19 |
| Atenolol | Atenolol | 85 | 13 |
| Xarelto | Rivaroxaban | 83 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 31 |
| Clonazepam | Clonazepam | 81 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 79 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 18 |
| Spironolactone | Spironolactone | 79 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 75 | 17 |
| Lansoprazole | Lansoprazole | 73 | 12 |
| Celecoxib | Celecoxib | 70 | 13 |
| Clonidine Hcl | Clonidine Hcl | 67 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 64 | 12 |
| Prednisone | Prednisone | 64 | 19 |
| Benztropine Mesylate | Benztropine Mesylate | 63 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 63 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 16 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 59 | 43 |
| Paroxetine Hcl | Paroxetine Hcl | 58 | suppressed |
| Ibuprofen | Ibuprofen | 56 | 20 |
| Propranolol Hcl | Propranolol Hcl | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | suppressed |
| Lorazepam | Lorazepam | 53 | 21 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Bumetanide | Bumetanide | 50 | 12 |
| Insulin Aspart Flexpen | Insulin Aspart | 50 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 48 | suppressed |
| Nystatin | Nystatin | 47 | 28 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 14 |
| Ezetimibe | Ezetimibe | 45 | 11 |
| Allopurinol | Allopurinol | 44 | suppressed |
| Alprazolam | Alprazolam | 44 | suppressed |
| Lumigan | Bimatoprost | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | suppressed |
| Entresto | Sacubitril/Valsartan | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 15 |
| Lidocaine | Lidocaine | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 13 |
| Olanzapine Odt | Olanzapine | 41 | suppressed |
| Digoxin | Digoxin | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Brilinta | Ticagrelor | 38 | suppressed |
| Sucralfate | Sucralfate | 38 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 11 |
| Diazepam | Diazepam | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Glipizide | Glipizide | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Aripiprazole Odt | Aripiprazole | 31 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 30 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Folic Acid | Folic Acid | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | 14 |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Haloperidol | Haloperidol | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 17 |
| Prednisolone Acetate | Prednisolone Acetate | 23 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Cephalexin | Cephalexin | 20 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Nexletol | Bempedoic Acid | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Methocarbamol | Methocarbamol | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Scopolamine | Scopolamine | 16 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 16 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 15 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Insulin Aspart | Insulin Aspart | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 15 | suppressed |
| Nystop | Nystatin | 15 | 14 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Bicalutamide | Bicalutamide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Novofine Plus | Pen Needle, Diabetic | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tetrabenazine | Tetrabenazine | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $790.48 · 14 records | UCB, Inc. | AUSTEDO XR, Briviact, FARXIGA, INSPIRE, Korlym, MOUNJARO, NEXLETOL, Nayzilam, REXULTI, UPLIZNA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error